|
1
|
Torre LA, Bray F, Siegel RL, Ferlay J,
Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA
Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
McCulloch M, Broffman M, van der Laan M,
Hubbard A, Kushi L, Abrams DI, Gao J and Colford JM: Colon cancer
survival with herbal medicine and vitamins combined with standard
therapy in a whole-systems approach: Ten-year follow-up data
analyzed with marginal structural models and propensity score
methods. Integr Cancer Ther. 10:240–259. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Liu AM, Xu Z and Luk JM: An update on
targeting Hippo-YAP signaling in liver cancer. Expert Opin Ther
Targets. 16:243–247. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Hong L, Cai Y, Jiang M, Zhou D and Chen L:
The Hippo signaling pathway in liver regeneration and
tumorigenesis. Acta Biochim Biophys Sin (Shanghai). 47:46–52. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Zhang X, George J, Deb S, Degoutin JL,
Takano EA, Fox SB; AOCS Study group, ; Bowtell DD and Harvey KF:
The Hippo pathway transcriptional co-activator, YAP, is an ovarian
cancer oncogene. Oncogene. 30:2810–2822. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Su LL, Ma WX, Yuan JF, Shao Y, Xiao W and
Jiang SJ: Expression of Yes-associated protein in non-small cell
lung cancer and its relationship with clinical pathological
factors. Chin Med J (Engl). 125:4003–4008. 2012.PubMed/NCBI
|
|
7
|
Xu MZ, Yao TJ, Lee NP, Ng IO, Chan YT,
Zender L, Lowe SW, Poon RT and Luk JM: Yes-associated protein is an
independent prognostic marker in hepatocellular carcinoma. Cancer.
115:4576–4585. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Zhang J, Xu ZP, Yang YC, Zhu JS, Zhou Z
and Chen WX: Expression of Yes-associated protein in gastric
adenocarcinoma and inhibitory effects of its konckdown on gastric
cancer cell proliferation and metastasis. Int J Immunopathol
Pharmacol. 25:583–590. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Zhang L, Yang S, Chen X, Stauffer S, Yu F,
Lele SM, Fu K, Datta K, Palermo N, Chen Y and Dong J: The hippo
pathway effector YAP regulates motility, invasion, and
castration-resistant growth of prostate cancer cells. Mol Cell
Biol. 35:1350–1362. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Pan W, Wang Q, Zhang Y, Zhang N, Qin J, Li
W, Wang J, Wu F, Cao L and Xu G: Verteporfin can reverse the
paclitaxel resistance induced by YAP over-expression in HCT-8/T
cells without photoactivation through inhibiting YAP expression.
Cell Physiol Biochem. 39:481–490. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Ivery MT and Le T: Modeling the
interaction of paclitaxel with beta-tubulin. Oncol Res. 14:1–19.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Joo Y, Schumacher B, Landrieu I, Bartel M,
Smet-Nocca C, Jang A, Choi HS, Jeon NL, Chang KA, Kim HS, et al:
Involvement of 14-3-3 in tubulin instability and impaired axon
development is mediated by Tau. FASEB J. 29:4133–4144. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Jinawath N, Vasoontara C, Yap KL,
Thiaville MM, Nakayama K, Wang TL and Shih IM: NAC-1, a potential
stem cell pluripotency factor, contributes to paclitaxel resistance
in ovarian cancer through inactivating Gadd45 pathway. Oncogene.
28:1941–1948. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Zhang H, Ramakrishnan SK, Triner D,
Centofanti B, Maitra D, Gyorffy B, Sebolt-Leopold JS, Dame MK,
Varani J, Brenner DE, et al: Tumor-selective proteotoxicity of
verteporfin inhibits colon cancer progression independently of
YAP1. Sci Signal. 8:ra982015. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Brodowska K, Al-Moujahed A, Marmalidou A,
Meyer Zu Horste M, Cichy J, Miller JW, Gragoudas E and Vavvas DG:
The clinically used photosensitizer Verteporfin (VP) inhibits
YAP-TEAD and human retinoblastoma cell growth in vitro without
light activation. Exp Eye Res. 124:67–73. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Pei BX, Sun YS and Dong SH: Curative
effect of Abraxane in patients with non-small-cell lung cancer and
breast cancer. Chin Pharm J. 46:1851–1854. 2011.
|
|
18
|
Sakamoto J, Matsui T and Kodera Y:
Paclitaxel chemotherapy for the treatment of gastric cancer.
Gastric Cancer. 12:69–78. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Xia Y, Chang T, Wang Y, Liu Y, Li W, Li M
and Fan HY: YAP promotes ovarian cancer cell tumorigenesis and is
indicative of a poor prognosis for ovarian cancer patients. PLoS
One. 9:e917702014. View Article : Google Scholar : PubMed/NCBI
|
